Andere talen Curasight A/S

Aandelen

CURAS

DK0061295797

slotkoers NORDIC GROWTH MARKET Andere beurzen 00:00:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,96 ^DKK	+0,20%		+9,45%	-43,89%

16/04	Curasight A/S kondigt goedkeuring aan van klinische onderzoeksaanvraag (CTA) voor fase 2-onderzoek met uTRACE bij patiënten met prostaatkanker	CI
12/04	Curasight A/S kondigt wijzigingen in de Raad van Bestuur aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	22/04
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	16/04
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	16/04
Curasight announces change in the Board of Directors	12/04
Curasight A/S Announces Board Changes	12/04
BioStock: Curasight cancels rights issue and evaluates alternative financing	13/03
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	11/03
Notice of Annual General Meeting 2024	06/03
The subscription period in Curasight's rights issue begins today	23/02
Curasight publishes information memorandum in connection with forthcoming rights issue	22/02
Annual Report for the fiscal year 2023	22/02
Year-end report October - December 2023	22/02
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	19/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13/02
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	13/02
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	13/02
BioStock: Curasight gets first milestone payment from Curium	02/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Curasight A/S

Aandelen

CURAS

DK0061295797

Andere talen

Filters